🔴 Amneal Pharmaceuticals is trading 5% down today following a multi-day rally into its Q2 report

Amneal Pharmaceuticals is trading 5% down at $18.15 today as the stock pulls back from a multi-day rally despite reporting strong second-quarter 2026 results.

• The company reported 10% year-over-year revenue growth to $796 million and raised its full-year 2026 revenue and EBITDA guidance.
• Management highlighted a strategic pivot toward higher-margin specialty and biosimilars, bolstered by the upcoming acquisition of Kashiv BioSciences.
• Despite the raised outlook and earnings beat, shares are retreating as investors react to the report following a significant run-up in share price.